Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.59 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.56 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.56 |
| ▸ | TSHR | P16473 | 3/20 | 0.54 |
| ▸ | MEN1 | O00255 | 2/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.52 |
| ▸ | HTT | P42858 | 1/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1275146 | 0.79 | POLB (0.64) | POLBCYP2C9CYP2C19TSHRMEN1 | |
| SCHEMBL2942696 | 0.79 | POLB (0.59) | POLBCYP2C9CYP2C19TSHRMEN1 | |
| SCHEMBL4590439 | 0.79 | POLB (0.59) | POLBCYP2C9CYP2C19TSHRMEN1 | |
| SCHEMBL81834 | 0.76 | CYP2C9 (0.57) | POLBCYP2C9CYP2C19TSHRMEN1 | |
| SCHEMBL1520616 | 0.75 | POLB (1.00) | POLBCYP2C9CYP2C19TSHRMEN1 | |
| SCHEMBL23718184 | 0.72 | TSHR (0.84) | POLBCYP2C9CYP2C19TSHRMEN1 | |
| SCHEMBL5872380 | 0.72 | CYP2C19 (1.00) | POLBCYP2C9CYP2C19TSHRMEN1 | |
| SCHEMBL11766353 | 0.71 | POLB (0.67) | POLBCYP2C9CYP2C19TSHRMEN1 | |
| SCHEMBL8956213 | 0.71 | SMN1; SMN2 (0.41) | POLBTSHRMEN1KMT2AALDH1A1 | |
| SCHEMBL6894899 | 0.70 | POLB (0.57) | POLBCYP2C9CYP2C19TSHRMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1765866-B1 | ISOLATION OF PLASMA OR SERUM PROTEINS | THERAPURE BIOPHARMA INC (CA) | 2014-01-08 | — | — | EP | claimed |
| EP-2051861-B1 | POROUS MEMBRANE AND ITS METHOD OF MANUFACTURE | FUJIFILM MFG EUROPE BV (NL) | 2011-03-23 | — | — | EP | claimed |
| US-9782468-B2 | Purification of polysaccharide protein conjugates | SHANTHA BIOTECHNICS PRIVATE LIMITED (IN) | 2017-10-10 | — | — | US | disclosed |
| EP-2139573-B1 | EXPANDED BED COLUMN AND DISPOSABLE CHROMATOGRAPHY | DPX HOLDINGS BV (NL) | 2016-11-09 | — | — | EP | disclosed |
| EP-2999709-A1 | PURIFICATION OF POLYSACCHARIDE PROTEIN CONJUGATES | Shantha Biotechnics Private Limited (IN) | 2016-03-30 | — | — | EP | disclosed |
| US-20160067325-A1 | Purification of Polysaccharide Protein Conjugates | SHANTHA BIOTECHNICS PRIVATE LIMITED (IN) | 2016-03-10 | — | — | US | disclosed |
| US-9220997-B2 | Expanded bed column and disposable chromatography | DPX HOLDINGS B.V. (NL) | 2015-12-29 | — | — | US | disclosed |
| US-8399620-B2 | Purification of factor VIII using a mixed-mode or multimodal resin | NOVO NORDISK A/S (DK) | 2013-03-19 | — | — | US | disclosed |
| EP-2167526-B1 | PURIFICATION OF FACTOR VIII USING A MIXED-MODE OR MULTIMODAL RESIN | NOVO NORDISK AS (DK) | 2011-03-30 | — | — | EP | disclosed |
| US-20100204452-A1 | Purification of Factor VIII Using a Mixed-Mode or Multimodal Resin | NOVO NORDISK HEALTH CARE AG (CH) | 2010-08-12 | — | — | US | disclosed |
| US-7750129-B2 | Process for the purification of antibodies | GE HEALTHCARE BIO-SCIENCES AB (SE) | 2010-07-06 | — | — | US | disclosed |
| WO-2009007451-A1 | PURIFICATION OF FACTOR VIII USING A MIXED-MODE OR MULTIMODAL RESIN | NOVO NORDISK A/S (DK) | 2009-01-15 | — | — | WO | disclosed |
| WO-2008116935-A1 | EXPANDED BED COLUMN AND DISPOSABLE CHROMATOGRAPHY | UPFRONT CHROMATOGRAPHY A/S (DK) | 2008-10-02 | — | — | WO | disclosed |
| US-7385040-B2 | contacting the solution with a chromatography resin containing a support to which multi-modal ligands have been immobilised ( N-hydroxysuccinimide activated agarose carrier coupled with 3-amino-4(propylsulfonyl)thiophene-2-carboxylic acid ligand) to adsorb antibodies and/or contaminants to the resin | GE HEALTHCARE BIO-SCIENCES AB (SE) | 2008-06-10 | — | — | US | disclosed |
| US-20070167613-A1 | Process for the purification of antibodies | CYTIVA BIOPROCESS R&D AB (SE) | 2007-07-19 | — | — | US | disclosed |
| US-20070112178-A1 | contacting the solution with a chromatography resin containing a support to which multi-modal ligands have been immobilised ( N-hydroxysuccinimide activated agarose carrier coupled with 3-amino-4(propylsulfonyl)thiophene-2-carboxylic acid ligand) to adsorb antibodies and/or contaminants to the resin | CYTIVA BIOPROCESS R&D AB (SE) | 2007-05-17 | — | — | US | disclosed |
| EP-1718668-A1 | ANTIBODY PURIFICATION | GE Healthcare Bio-Sciences AB (SE) | 2006-11-08 | — | — | EP | disclosed |
| EP-1718386-A1 | A PROCESS FOR THE PURIFICATION OF ANTIBODIES | GE Healthcare Bio-Sciences AB (SE) | 2006-11-08 | — | — | EP | disclosed |
| WO-2005082483-A1 | A PROCESS FOR THE PURIFICATION OF ANTIBODIES | GE HEALTHCARE BIO-SCIENCES AB (SE) | 2005-09-09 | — | — | WO | disclosed |
| WO-2005082926-A1 | ANTIBODY PURIFICATION | GE HEALTHCARE BIO-SCIENCES AB (SE) | 2005-09-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070112178-A1 | contacting the solution with a chromatography resin containing a support to which multi-modal ligands have been immobilised ( N-hydroxysuccinimide activated agarose carrier coupled with 3-amino-4(propylsulfonyl)thiophene-2-carboxylic acid ligand) to adsorb antibodies and/or contaminants to the resin | ATIC, ARSA, SLC7A1 | POLB 4507/4885CYP2C9 4637/4885CYP2C19 4830/4885 |
| US-20070167613-A1 | Process for the purification of antibodies | FCGR1A, FCGRT, CD47 | POLB 4008/4885CYP2C9 2767/4885CYP2C19 3753/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.